UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

Nature biotechnology, 2023-09, Vol.41 (9), p.1296-1306

2023

Volltextzugriff (PDF)

852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A893-A893

2021

Volltextzugriff (PDF)

An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities

Molecular cancer therapeutics, 2020-08, Vol.19 (8), p.1660-1669

2020

Volltextzugriff (PDF)

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma

Blood, 2022-02, Vol.139 (8), p.1160-1176

2022

Volltextzugriff (PDF)

The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape

Lung cancer (Amsterdam, Netherlands), 2023-10, Vol.184, p.107356-107356, Article 107356

2023

Volltextzugriff (PDF)

Translational Model‐Based Strategy to Guide the Choice of Clinical Doses for Antibody–Drug Conjugates

Journal of clinical pharmacology, 2017-07, Vol.57 (7), p.865-875

2017

Volltextzugriff (PDF)

Abstract 3269: Ablation of Cbl-b gene function leads to increased activation and resistance to immunosuppression in human primary T lymphocytes

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3269-3269

2020

Volltextzugriff (PDF)

Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours

Tumor biology, 2012-10, Vol.33 (5), p.1709-1717

2012

Volltextzugriff (PDF)

Abstract 5340: NK-humanized mouse models for the in vivo evaluation of NK cell-based therapies in solid tumors

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5340-5340

2024

Volltextzugriff (PDF)

Abstract 2266: SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2266-2266

2020

Volltextzugriff (PDF)

Abstract 2940: Use of NK humanized mouse models for the in vivo evaluation of anti-tumor NK-cell therapies

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2940-2940

2023

Volltextzugriff (PDF)

Abstract 4247: Development of NK humanized mice models for the in vivo evaluation of NK cell engagers

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.4247-4247

2022

Volltextzugriff (PDF)

Cationic lipids for transfection

Current medicinal chemistry, 2003-07, Vol.10 (14), p.1263-1277

2003

Volltextzugriff (PDF)

Abstract LB-053: Towards new cryptophycins as promising payloads for ADC

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.LB-053-LB-053

2016

Volltextzugriff (PDF)

Physicochemical optimisation of plasmid delivery by cationic lipids

The journal of gene medicine, 2004-02, Vol.6 (S1), p.S24-S35

2004

Volltextzugriff (PDF)

Abstract B145: PK/PD evaluation of an anti-CEACAM5 antibody drug conjugate, in a colon patient-derived-xenografted mice model

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B145-B145

2015

Volltextzugriff (PDF)

Abstract 1688: A novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1688-1688

2015

Volltextzugriff (PDF)

Abstract 5179: Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5179-5179

2020

Volltextzugriff (PDF)

Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4735-4735

2013

Volltextzugriff (PDF)

Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia

Molecular cancer therapeutics, 2021-10, Vol.20 (10), p.1916-1925

2021

Volltextzugriff (PDF)

Abstract 3740: Tusamitamab ravtansine induces immunogenic cell death and synergizes with anti-PD-1 or anti-PD-L1 antibody combination in solid tumor

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3740-3740

2024

Volltextzugriff (PDF)

Abstract 561: Preclinical efficacy data for the anti-CEACAM5-DM4 ADC SAR408701 supports further development in lung and gastro-intestinal cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.561-561

2020

Volltextzugriff (PDF)

Abstract 1334: Evaluation of NK cell combination therapies in mouse models of cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1334-1334

2024

Volltextzugriff (PDF)

Abstract 2118: SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2118-2118

2024

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Cancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Animals
(9)
Humans
(8)
Mice
(7)
Pharmacology & Pharmacy
(5)
Oncology
(4)
Biochemistry & Molecular Biology
(3)
Biological And Medical Sciences
(3)
Chemistry
(3)
Female
(3)
Life Sciences
(3)
Lipids
(3)
Medical Sciences
(3)
Pharmacology. Drug Treatments
(3)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(2)
Antibodies
(2)
Antibody-Dependent Cell Cytotoxicity
(2)
Antiviral Agents
(2)
Biomedical And Life Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC

An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma

The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

Translational Model‐Based Strategy to Guide the Choice of Clinical Doses for Antibody–Drug Conjugates

Abstract 3269: Ablation of Cbl-b gene function leads to increased activation and resistance to immunosuppression in human primary T lymphocytes

Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours

Abstract 5340: NK-humanized mouse models for the in vivo evaluation of NK cell-based therapies in solid tumors

Abstract 2266: SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma

Abstract 2940: Use of NK humanized mouse models for the in vivo evaluation of anti-tumor NK-cell therapies

Abstract 4247: Development of NK humanized mice models for the in vivo evaluation of NK cell engagers

Cationic lipids for transfection

Abstract LB-053: Towards new cryptophycins as promising payloads for ADC

Physicochemical optimisation of plasmid delivery by cationic lipids

Abstract B145: PK/PD evaluation of an anti-CEACAM5 antibody drug conjugate, in a colon patient-derived-xenografted mice model

Abstract 1688: A novel anti-CEACAM5 maytansinoid-antibody-drug conjugate for the treatment of colorectal, lung and gastric tumors

Abstract 5179: Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia

Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies

Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia

Abstract 3740: Tusamitamab ravtansine induces immunogenic cell death and synergizes with anti-PD-1 or anti-PD-L1 antibody combination in solid tumor

Abstract 561: Preclinical efficacy data for the anti-CEACAM5-DM4 ADC SAR408701 supports further development in lung and gastro-intestinal cancers

Abstract 1334: Evaluation of NK cell combination therapies in mouse models of cancer

Abstract 2118: SGN-CEACAM5C/SAR445953, a novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5, has potent anti-tumor activity in CRC, PDAC, GC and lung cancer tumor models

Aktive Filter

Suchergebnisse filtern